Evidence map›Paper›PMID 33970955›Full record

ArticlePloS one2021

Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis.

Daniel Sammartino, Farrukh Jafri, Brennan Cook, Lisa La, Hyemin Kim, John Cardasis, Joshua Raff

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daniel SammartinoWhite Plains Hospital, White Plains, New York, United States of America.ORCID 0000-0003-2932-5012
Farrukh JafriWhite Plains Hospital, White Plains, New York, United States of America.
Brennan CookRutgers Robert Wood Johnson School of Medicine, New Brunswick, New Jersey, United States of America.
Lisa LaWhite Plains Hospital, White Plains, New York, United States of America.
Hyemin KimWhite Plains Hospital, White Plains, New York, United States of America.
John CardasisWhite Plains Hospital, White Plains, New York, United States of America.
Joshua RaffWhite Plains Hospital, White Plains, New York, United States of America.ORCID 0000-0001-6934-2170
White Plains Hospital · USRutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) pandemic overwhelmed healthcare systems, highlighting the need to better understand predictors of mortality and the impact of medical interventions.

methodsThis retrospective cohort study examined data from every patient who tested positive for COVID-19 and was admitted to White Plains Hospital between March 9, 2020, and June 3, 2020. We used binomial logistic regression to analyze data for all patients, and propensity score matching for those treated with hydroxychloroquine and convalescent plasma (CP). The primary outcome of interest was inpatient mortality.

results1,108 admitted patients with COVID-19 were available for analysis, of which 124 (11.2%) were excluded due to incomplete data. Of the 984 patients included, 225 (22.9%) died. Risk for death decreased for each day later a patient was admitted [OR 0.970, CI 0.955 to 0.985; p < 0.001]. Elevated initial C-reactive protein (CRP) value was associated with a higher risk for death at 96 hours [OR 1.007, 1.002 to 1.012; p = 0.006]. Hydroxychloroquine and CP administration were each associated with increased mortality [OR 3.4, CI 1.614 to 7.396; p = 0.002, OR 2.8560, CI 1.361 to 6.160; p = 0.006 respectively].

conclusionsElevated CRP carried significant odds of early death. Hydroxychloroquine and CP were each associated with higher risk for death, although CP was without titers and was administered at a median of five days from admission. Randomized or controlled studies will better describe the impact of CP. Mortality decreased as the pandemic progressed, suggesting that institutional capacity for dynamic evaluation of process and outcome measures may benefit COVID-19 survival.

Indexed as

Hospital MortalityAdultAgedAged, 80 and overAntiviral AgentsCOVID-19COVID-19 Drug TreatmentC-Reactive ProteinFemaleHospitalizationHumansHydroxychloroquineLogistic ModelsMaleMiddle AgedOdds RatioAntiviral AgentsC-Reactive ProteinHydroxychloroquine

Identifiers

PMID33970955
PMCPMC8109786
OpenAlexW3160077157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.